Orphenadrine

In response to the problems of limited motor function and decreased quality of life caused by Parkinson's disease and musculoskeletal pain, the clinical value of central muscle relaxants has become increasingly prominent. Orphenadrine is a central muscle relaxant derived from antihistamines. It can reduce skeletal muscle tension by blocking the nerve conduction pathways in the brain stem and spinal cord, and also has a mild analgesic effect. Clinically, it is mainly used to relieve acute muscle spasm pain caused by muscle sprain, strain, intervertebral disc herniation, etc. It can also be used as an adjuvant therapeutic drug for Parkinson's disease. The applicable population includes patients with middle-aged and elderly degenerative diseases, people with sports injuries and patients requiring muscle relaxation intervention after surgery.

At present, the global market size of orphenadrine is about USD 320 million, with a compound annual growth rate maintained at around 2.8%. The growth momentum mainly comes from the rising prevalence of chronic musculoskeletal diseases and the expansion of treatment demand for elderly neurodegenerative diseases. In terms of the domestic market, this variety has not been included in the national centralized procurement. The existing supply is dominated by generic drugs, and local enterprises account for more than 75% of the overall market share. The original research product is only used in a small number of high-end self-paid medical scenarios. If there is no verifiable data, please indicate it directly.

The original research enterprise of orphenadrine is Johnson & Johnson, with the original research brand name Norflex. The core compound patent expired globally in 1980. The main dosage forms of the original research include 100mg oral tablets and 30mg/mL injections, among which the 100mg oral tablets have been included in the FDA Reference Listed Drug Catalog. As of the retrieval time point, China NMPA has approved 8 orphenadrine oral preparations and 2 injections for marketing. There are 6 orphenadrine API registration numbers in the CDE API registration platform, 3 of which are in status A and can be legally supplied for the production of associated preparations. (Data as of June 2025, please refer to the official CDE website for the latest information.)

CATO provides a full set of impurity reference standards for orphenadrine API. Most of the products are in stock. For in-stock products, orders placed before 16:00 will be shipped on the same day. All reference standards comply with the regulatory requirements of the Chinese Pharmacopoeia, FDA and other regulations, and can fully meet the needs of pharmaceutical enterprises in the whole process of drug research and development, quality control and registration declaration.